



Department of Obstetrics and Gynaecology
Queen Mary Hospital
The University of Hong Kong



Gynaecological Oncology

Annual Report 2018



Gynaecological Oncology

Department of Obstetrics and Gynaecology
Queen Mary Hospital
The University of Hong Kong

Annual Report 2018



**HKU
Med**

LKS Faculty of Medicine
Department of Obstetrics
& Gynaecology
香港大學婦產科學系

Message from Division Head

The gynaecological oncology division of the Department of Obstetrics and Gynaecology, the University of Hong Kong, has been providing training and service in gynaecological oncology for over 50 years. Our unit is a tertiary referral center for both the private and public sectors in Hong Kong. We also accept referrals from the hospitals in Macau. With collaboration with other departments, our scope of services includes colposcopy, chemotherapy, radiotherapy, surgery and palliative care.

Our unit is a recognized training center for gynaecological oncology by the Hong Kong College of Obstetricians and Gynaecologists (HKCOG) and the Royal College of Obstetricians and Gynaecologists (RCOG). In 2018, we had Dr. Carmen Choi with us for her third year of subspecialist training in gynaecological oncology. Apart from training subspecialist fellow, we also provide gynaecological oncology training for basic and higher specialist trainees in Obstetrics and Gynaecology, not only from our unit but also other hospitals in Hong Kong.

In November 2018, we invited Professor Sean Kehoe, a gynaecologic oncologist from the University of Birmingham in the United Kingdom as the 33rd Aw Boon Haw Visiting Professor. In December 2018, we held a Gynaecological Oncology Surgical Workshop and invited experts from overseas including: Professor Eric Leblanc from the Département de Cancérologie Gynécologique, Centre Oscar Lambret, Lille, France; Dr Peter Lim from the University of Nevada School of Medicine, The Center of Hope, Renown Regional Medical Center, Reno, Nevada, USA; and Dr. Tae Joong Kim from the Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.

In addition to the clinical service and research activities, our division was also active in promoting women's health in Hong Kong by giving public talks and presentation in the Family Planning Association, radio and TV programmes. In October 2018, our unit has organized the annual event of Care You Deserve Charity Walk with The Hong Kong Anti-Cancer Society with an aim to increase the public awareness to women's cancer.

I would like to take this opportunity to thank our team members and our collaborators for their contribution



H.Y.S. Ngan
Tso Yin-Kai Professor
Head of Department

Table of contents

I	Staff List	4
II	Laboratory	7
III	Inpatient & Outpatient Services	9
IV	Team Activities	10
V	Outpatient Statistics	11
VI	Colposcopy Services	12
VII	Cervical Malignancies	14
VIII	Uterine Malignancies	15
IX	Ovarian Malignancies	17
X	Gestational Trophoblastic Neoplasia	19
XI	Vulval, Vaginal and Fallopian Tube Cancers	20
XII	Multiple Primary Malignancies	22
XIII	Operations for Malignant/Pre-malignant Diseases	23
XIV	Chemotherapy	25
XV	Publications and Abstracts	27

Staff List

Gynaecological Oncologists

Professor Ngan Yuen Sheung Hextan, Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chan Kar Loen Karen, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Tse Ka Yu, Associate Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Dr. Chu Man Yee Mandy, Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital

Dr. Ngu Siew Fei, Assistant Professor, Department of Obstetrics and Gynaecology, University of Hong Kong

Subspecialist Trainee

Dr. Choi Ka Man Carmen, Associate Consultant, Department of Obstetrics and Gynaecology, Pamela Youde Nethersole Eastern Hospital

Specialist Gynaecologists

Dr. Cheng Mei Chi Maggie, Associate Consultant, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jan – 30 Jun 2018)

Dr. Chung Carmen Diana, Resident Specialist, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jul – 31 Dec 2018)

Residents

Dr. Ng Wai Yan Vivian, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (15 Feb – 31 Mar 2018)

Dr. Lai Hei Tung Theodora, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Apr – 15 May 2018)

Dr. Tong Yu Wing Paul, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Jul – 30 Sep 2018)

Dr. Ip Nga Ping Patricia, Resident, Department of Obstetrics and Gynaecology, Queen Mary Hospital (1 Dec – 30 Dec 2018)

Clinical Oncologists

Dr. Luk Mei Yee, Chief of Service, Department of Clinical Oncology, Queen Mary Hospital

Dr. Kwong Wai Kay Philip, Consultant, Department of Clinical Oncology, Queen Mary Hospital

Dr. Liu Rico, Consultant, Department of Clinical Oncology, Queen Mary Hospital

Dr. Siu Wai Kwan Steven, Associate Consultant, Department of Clinical Oncology, Queen Mary Hospital

Pathologists

Professor Ng Oi Lin Irene, Head of Department, Department of Pathology, University of Hong Kong

Professor Cheung Nga Yin Annie, Professor, Department of Pathology, University of Hong Kong

Dr. Ip Pun Ching Philip, Associate Professor, Department of Pathology, Queen Mary Hospital

Consultant Colorectal Surgeon

Professor Law Wai Lun, Professor, Department of Surgery, Queen Mary Hospital

Dr. Ho Judy, Consultant, Department of Surgery, Queen Mary Hospital

Consultant Urologist

Dr. Tsu Hok Leung James, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

Consultant Plastic Surgeon

Dr. Chow Ling Yu Velda, Consultant & Division Chief, Department of Surgery, Queen Mary Hospital

Consultant Medical Oncologist

Professor Kwong Yok Lam, Division of Haematology, Medical Oncology and Bone Marrow Transplantation, Department of Medicine, University of Hong Kong

Consultant Radiologist

Dr. Lam Wai Man Wendy, Chief of Service, Department of Radiology, Queen Mary Hospital

Dr. Lee Yuen Phin Elaine, Assistant Professor, Department of Radiology, University of Hong Kong

Consultant Anaesthesiologist

Professor Michael Irwin, Chief of Service, Department of Anaesthesiology, Queen Mary Hospital

Consultant Clinical Psychologist

Dr. Lina Wu, Senior Clinical Psychologist, Department of Psychiatry, Queen Mary Hospital

Medical Social Workers

Ms Lui Man Li, Social Welfare Department

Nurse Specialist in Stoma Care

Ms. Chan Lai Hung, Nursing Officer, Queen Mary Hospital

Cluster Rehabilitative Palliative Care Team

Dr. Chan Kwok Ying, Consultant, Palliative Medicine Unit, Grantham Hospital

Dr. Li Cho Wing Brian, Associate Consultant, Palliative Medicine Unit, Grantham Hospital

Ms. Ho Suk Hing, Registered Nurse, Grantham Hospital

Clinical Research Team

Ms Lau Suk Kwan Lesley, Research Co-ordinator

Dr. Wei Na Tina, Research Co-ordinator

Ms. Chan Kin Yan Janice, Research Assistant

Ms. Yu Ping Ching Amy, Research Nurse (part-time)

Laboratory

Staff

Dr. Chan Wai David, Assistant Professor
Dr. Leung Ho Yin Thomas, Post-doctoral Fellow
Dr. Yung Ming Ho Mingo, Post-doctoral Fellow
Dr. Liu Si Stephanie, Research Officer
Dr. Siu Kwan Yee Michelle, Research Officer
Mr. Chan Chan Keung Milton, Technician
Dr. Chan Yau Sang, Senior Research Assistant
Dr. Chu Kit Hang Daniel, Research Assistant
Miss Tang Wai Man Hermit, Research Assistant
Miss HUI Man Ning, Lynn, Research Assistant
Miss Lo Sze Victoria, Research Assistant

Services

Hormonal assay and assays for tumour markers

Research tools

HPV detection and genotyping	
ELISA	Cell line and culture
Immunohistochemistry	Transfection study
In situ hybridization assay	RNAi study
DNA, RNA and protein extractions	Apoptotic assay
Conventional PCR and RT-PCR	Clonogenic assay
Quantitative PCR	Cytotoxicity assay
Quantitative RT-PCR	Cell proliferation assay
RNA protection assay	DNA copy number variation analysis
Western blot	Protein co-immunoprecipitation
DNA methylation analysis	Gene cloning
DNA sequencing	In vivo animal study
Microarray analysis	Laser-captured microdissection
Hypoxia chamber	
Flow cytometry	
Yeast two hybrid	

Fluorescent microscopy

Fluorescent stereomicroscopy

Li-Cor Odyssey CLx near-infrared fluorescence imaging system

Gel documentation system

Microplate reader

SpectraMax L Microplate Reader

Inpatient Services

Gynaecological oncology ward

22 beds in the open ward
2 private beds
3 day beds

Ward Manager

Ms. Hui Fung Ping, Susanna

Operating Theatre

2 Full-day lists per week

Operating Theatre Manager

Ms. Sylvia Wong

Outpatient Services

Colposcopy Clinic	4 sessions per week
Chemotherapy Clinic	1 session per week
Cancer follow-up Clinic	1 session per week
Trophoblastic Clinic	1 session per week
Day Chemotherapy	5 days per week
Patient Group Meeting	1 session per 3 weeks
Palliative Medicine Clinic	1 session per week
Pre-admission Clinic	1 session per week

Clinic In-charge

Ms. Chung Suk Man, Advanced Practice Nurse, S5, Queen Mary Hospital

Team Activities

Grand Round (Led by Prof. Hextan Ngan)	1 per week
Discussion of New Cases and Treatment (Led by Prof. Hextan Ngan)	1 per week
Radiology Meeting (Led by Prof. Hextan Ngan and Dr. Elaine Lee)	1 per week
Chemotherapy Meeting (Led by Prof. Hextan Ngan)	1 per week
Morbidities and Mortality Meeting (Led by Prof. Hextan Ngan)	1 per week
Pre-operative Round (Led by Prof. Hextan Ngan)	1 per week
Tumour Board Meeting/Pathology Review (Led by Prof. Hextan Ngan and Prof. Annie Cheung)	1 per week
Laboratory Research Meeting (Led by Prof. Hextan Ngan)	1 per month
Clinical Research Meeting (Led by Prof. Hextan Ngan)	1 per month

Outpatient Statistics

<i>Oncology Clinics Attendances</i>	2014	2015	2016	2017	2018
Cancer Follow-up Clinic	4244	4249	4010	4183	4322
Trophoblastic Clinic	795	766	907	856	726
Chemotherapy Clinic	1879	2082	1894	1758	2044
Preadmission Clinic	-	-	-	-	95

Patient Group Meeting

Oncology patients support group which was led by:

Ms. Susanna Hui (Ward Manager)
Ms. Tang Lai Chun (Advanced Practice Nurse)
Ms. Cheng Sze Ki (Registered Nurse)
Ms Tam Siu Man (Registered Nurse)

Stoma patients support group which was led by:

Ms. Susanna Hui (Ward Manager)
Ms. Chan Lai Hung (Nursing Officer)
Ms Tam Siu Man (Registered Nurse)

Oncology patient support group:

Total no. of sessions: 6

Total no. of attendance: 33 patients + 21 relatives = 54

Stoma patient support group:

Total no. of sessions: 3

Total no. of attendance: 28 patients + 3 relatives = 31

Annual patient group party:

Attendance: 64 patients + 15 relatives = 79

Colposcopy Services

Colposcopy Clinics

Queen Mary Hospital

4 sessions - Monday afternoon, Tuesday morning, Thursday and Friday afternoon

1 research session – Wednesday afternoon

Cervical Smear Clinics (run by nurses)

Queen Mary Hospital

3 session - Monday afternoon, Tuesday morning and Thursday afternoon

WDTC

4 sessions - Monday and Tuesday (full day)

Statistics

New Cases	569
Follow-up	1589


Diagnosis (based on worst histology)	Cervix	Vagina	Vulva
Normal	102	9	0
Inflammation	41	0	0
Warts/HPV	105	6	0
Low grade squamous intraepithelial lesion	190	20	0
High grade squamous intraepithelial lesion	102	17	1
Microinvasive carcinoma	3	0	0
Squamous cell carcinoma	4	0	0
Adenocarcinoma	3	1	0
Adenocarcinoma in-situ	2	0	0
No histology	88	19	3
Unsatisfactory for assessment	10	2	0
Others			
Atrophy	1	1	
Atypical cells	1		
Endocervical polyp	6		
Intestinal metaplasia	1		
Lichen sclerosus			1
Mycobacterial infection	1		

Procedures

Cone biopsy	4
Cryotherapy	1
Large loop excision of transformation zone	115
Under local anaesthesia	101
Under general / spinal anaesthesia	14

Cervical Malignancies

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Number of New cases	62	87	98	62	83	84	82	87	101	73	84
Stage I	28	49	36	26	36	42	42	43	36	36	33
Stage II	25	17	35	27	22	21	19	17	26	18	24
Stage III	8	13	11	4	15	16	14	12	14	11	11
Stage IV	1	4	5	3	5	3	2	6	8	3	9
Unstaged	0	2	3	1	1	1	3	0	5	2	4
Recurrence	0	2	8	1	4	1	2	9	12	3	3




2018 New Case

Stage	Age	Count
Stage I	≤ 30	1
Stage II	31-40	14
Stage III	41-50	19
Stage IV	51-60	22
Unstaged	61-70	12
Recurrence	71-80	12
Total	> 80	4
	Total	84

Uterine Malignancies

Carcinoma of Endometrium

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Number of New cases	87	81	100	78	110	121	146	115	134	128	147
Stage I	43	43	64	45	64	70	83	69	88	81	88
Stage II	10	7	10	5	10	8	16	10	10	11	14
Stage III	21	10	15	16	23	25	26	18	23	24	26
Stage IV	6	4	4	5	4	5	12	7	9	6	13
Unstaged	3	12	6	4	7	10	8	7	2	3	5
Recurrence	4	5	1	3	2	3	1	4	2	3	1



2018 New Case

Stage	Age	Number of Cases
Stage I	≤ 30	1
Stage II	31-40	11
Stage III	41-50	31
Stage IV	51-60	47
Unstage	61-70	41
Recurrence	71-80	9
Total	> 80	7
	Total	147


Other Uterine Malignancies

	2014	2015	2016	2017	2018
Endometrial stromal sarcoma	3	3	5	3	8
Leiomyosarcoma	6	6	5	14	7
Malignant mixed mullerian tumor (MMMT)	14	5	8	11	8
Adenosarcoma	2	0	0	1	0
Chondrosarcoma	0	0	0	1	0
Rabdomyosarcoma	0	0	0	1	0
Smooth muscle tumour of undetermined malignant potential (STUMP)	1	1	3	0	1
Dedifferentiated endometrial carcinoma	0	0	0	1	0
Undifferentiated endometrial sarcoma	0	2	0	0	0
Uterine tumour resembling ovarian sex cord tumour	0	0	0	1	0
Uterine small cell carcinoma	0	0	1	0	1
Undifferentiated carcinoma	0	0	1	1	4

Ovarian Malignancies

Epithelial Ovarian Cancer

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Number of New cases	42	47	69	55	61	64	78	76	76	66	79
Stage I	12	21	21	22	26	30	25	22	32	14	27
Stage II	5	3	4	6	9	7	7	5	4	11	2
Stage III	9	11	13	21	16	16	32	33	16	22	14
Stage IV	8	4	15	6	4	10	9	10	13	12	14
Unstaged	1	0	7	0	2	1	1	1	2	1	1
Recurrence	7	8	9	0	4	0	4	5	9	6	21



2018 New Case

Stage	Age	Number of Cases
Stage I	≤ 30	2
Stage II	31-40	7
Stage III	41-50	31
Stage IV	51-60	24
Unstage	61-70	14
Recurrence	71-80	1
Total	> 80	0
Stage I	Total	79

Ovarian Tumour of Low Malignant Potential

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Number of new cases	21	15	13	8	19	19	19	18	13	22	12
Stage I	18	12	11	7	15	14	15	16	6	19	10
Stage II	0	0	0	0	0	2	1	0	1	2	0
Stage III	2	1	1	0	2	2	2	2	1	0	1
Unstaged	0	0	0	0	0	1	0	0	0	0	0
Recurrence	1	1	1	1	2	0	1	0	4	1	0

Germ Cell Tumour

1 patient had stage 1a immature teratoma

Sex Cord-Stromal Tumour

2 patients had stage Ia granulosa cell tumour

1 patient had stage 1c granulosa cell tumour

1 patient had stage 1a Sertoli-Leydig cell tumour

Other Ovarian Malignancies

1 patient had stage 2b carcinosarcoma of ovary

1 patient had stage 3a carcinosarcoma of ovary

1 patient had stage 3c undifferentiated adenocarcinoma or carcinosarcoma of ovary

1 patient had stage 4 poorly differentiated adenocarcinoma of ovary


1 patient had low grade sarcoma of ovary

Primary Peritoneal Carcinoma

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Total	8	10	19	3	13	10	10	9	15	9	11
Stage II				0	2	0	0	0	1	0	0
Stage III				1	5	7	4	7	9	1	6
Stage IV				2	5	3	4	1	4	3	4
Unstaged				0	1	0	1	0	1	4	1
Recurrence				0	0	0	1	1	0	1	0

Gestational Trophoblastic Neoplasia

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Number of New cases	12	9	15	10	21	16	17	14	12	10	12
Stage I	9	6	10	9	18	12	10	8	8	8	9
Stage II	0	1	1	1	0	0	1	0	0	0	1
Stage III	3	2	1	0	2	2	5	2	2	2	2
Stage IV	0	0	1	0	1	2	0	1	1	0	0
Unstaged	0	0	0	0	0	0	0	0	0	0	0
Recurrence	0	0	2	0	0	0	1	1	1	0	0



2018 New case

Stage	Age	Count
Stage I	≤ 30	3
Stage II	31-40	6
Stage III	41-50	2
Stage IV	> 50	1
recurrence	Total	12
Total		12

Vulval, Vaginal and Fallopian Tube Cancers

Vulval Cancer

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Number of											
New cases	8	8	11	5	8	7	9	6	6	9	12
Stage I	3	1	5	0	2	4	4	0	3	6	2
Stage II	3	2	0	0	1	0	0	1	0	0	4
Stage III	2	2	2	2	1	1	3	1	1	3	1
Stage IV	0	2	1	1	2	1	0	1	0	0	1
Unstaged	0	1	2	2	1	0	1	1	1	0	2
Recurrence	0	0	1	0	1	1	1	2	1	0	2

Vaginal Cancer

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
Number of											
New cases	4	4	0	5	8	3	3	5	7	5	5
Stage I	1	0	0	0	2	0	1	0	0	0	0
Stage II	1	2	0	4	1	1	1	4	5	1	3
Stage III	0	1	0	1	1	0	0	0	0	1	2
Stage IV	1	0	0	0	2	2	0	1	1	2	0
Unstaged	0	1	0	0	1	0	0	0	0	0	0
Recurrence	1	0	0	0	1	0	1	0	1	1	0

Fallopian Tube Cancer

Year	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018
New Cases	0	3	0	0	1	0	3	2	5	4	2
Stage I	0	1	0	0	1	0	0	0	0	1	0
Stage II	0	0	0	0	0	0	0	0	1	2	0
Stage III	0	1	0	0	0	0	1	0	2	0	1
Stage IV	0	1	0	0	0	0	2	2	1	1	0
Unstaged	0	0	0	0	0	0	0	0	0	0	0
Recurrence	0	0	0	0	0	0	0	0	1	0	1

Multiple Primary Malignancies

2018 Number
24

Primary	Stage	Primary	Stage	Number
Corpus	I	Ovarian Epithelial	I	5
	I	Ovarian Epithelial	II	4
	I	Ovarian Epithelial	III	2
	I	Cervix	I	2
	I	Fallopian tube	I	1
	I	Uterine STUMP		1
	I	Carcinoma of lung		1
	II	Ovarian Epithelial	I	1
	II	Ovarian Epithelial	II	1
	II	Ovarian Epithelial	IV	1
Cervix	I	Ovarian Epithelial	I	1
	II	Rectum	III	1
	III	Bladder	IV	1
Ovary		Ovarian Epithelial		
	I	(Different histology on contralateral side)	II	1
Ovary	I	Fallopian tube	I	1

Triple primary case - Nil

Operation for Malignant/Pre-malignant Diseases

	Number of procedures
Laparotomy (all cases with open abdominal surgery)	91
Radical hysterectomy +/- unilateral / bilateral salpingo-oophorectomy (U/BSO)	3
Laparoscopic radical hysterectomy +/- U/BSO	2
Laparoscopic radical hysterectomy +/- U/BSO (Da Vinci)	13
Modified radical hysterectomy +/- U/BSO	8
Laparoscopic modified radical hysterectomy +/- U/BSO (Da Vinci)	3
Total abdominal hysterectomy +/- U/BSO	65
Total laparoscopic hysterectomy +/- U/BSO	52
Total laparoscopic hysterectomy +/- U/BSO (Da Vinci)	26
Laparoscopic radical trachelectomy (Da Vinci)	0
Pelvic lymphadenectomy (one side)	73
Laparoscopic pelvic lymphadenectomy (one side)	28
Laparoscopic pelvic lymphadenectomy (one side) (Da Vinci)	74
Paraaortic lymphadenectomy	33
Laparoscopic paraaortic lymphadenectomy	3
Laparoscopic paraaortic lymphadenectomy (one side) (Da Vinci)	28
Omentectomy	47
Laparoscopic omentectomy	10
Laparoscopic omentectomy (Da Vinci)	11
Adhesiolysis	23
Laparoscopic adhesiolysis	5
Laparoscopic adhesiolysis (Da Vinci)	5
BSO / USO / ovarian cystectomy	15
Laparoscopic BSO / USO / ovarian cystectomy	4

Appendicectomy	8
Laparoscopic appendicectomy	3
Laparoscopic appendicectomy (Da Vinci)	0
Debulking surgery	28
Bowel resection and re-anastomosis	10
Colostomy / ileostomy	6
Closure of stoma	5
Repair of bowel	2
Repair of bladder	0
Repair of vessels	1
Repair of vagina / perineum	2
Vault stripping / vaginectomy	7
Wide local excision	7
Radical vulvectomy	7
Groin node dissection (one side)	8
Cone biopsy	2
Large loop excision of transformation zone	3
Brachytherapy	43
Removal or insertion of central line insertion	3
Diagnostic hysteroscopy	14
Hysteroscopic polypectomy	2
Suction evacuation	0
Laparoscopic myomectomy	1
Excision of vaginal lesion	1
Laparoscopic biopsy	6
Diagnostic laparoscopy	6
Examination under anaesthesia	2
Cystoscopy	0

Chemotherapy

Total number of patients receiving in-patient chemotherapy: 222

Total number of patients receiving out-patient chemotherapy: 237

Total number of patients receiving oral chemotherapy: 7

Total number of patients receiving PARP inhibitors: 12

Chemotherapy Regimen	Number of courses	
	In patient	Outpatient
Adriamycin	8	12
Adriamycin/Cisplatin	4	6
Adriamycin/Ifosfamide	14	0
*Avelumab	3	27
BEP (bleomycin, etoposide, cisplatin)	7	3
Bevacizumab	26	53
Carboplatin	2	18
Carboplatin/Etoposide	2	4
Carboplatin/Gemcitabine	46	63
Carboplatin/Gemcitabine/Bevacizumab	2	1
Carboplatin/Liposomal doxorubicin	2	8
Carboplatin/Paclitaxel	240	519
*Carboplatin/Paclitaxel/Avelumab	21	0
Carboplatin/Paclitaxel/Bevacizumab	17	23
Cisplatin	62	63
Cisplatin/Gemcitabine	5	15
Cisplatin/Gemcitabine/Bevacizumab	2	3
Cisplatin/Paclitaxel	10	0
Cisplatin/Paclitaxel/Bevacizumab	8	0
Cyclophosphamide (oral)	0	0
EMA-CO (etoposide, methotrexate and actinomycin D/ cyclophosphamide and vincristine)	23	0
EP-EMA (etoposide and cisplatin / etoposide, methotrexate, and actinomycin-D)	0	0
Etoposide (oral)	1	2
Gemcitabine	23	62

Gemcitabine/Taxotere	3	17
Ifosfamide	0	0
Ifosfamide/Paclitaxel	9	0
Liposomal doxorubicin	24	52
Liposomal doxorubicin/Bevacizumab	4	6
Melphalan	0	13
Methotrexate (intravenous)	30	0
Methotrexate/Actinomycin D	11	0
Olaparib	0	96
Pemetrexed	2	6
Paclitaxel	8	1
Paclitaxel/Bevacizumab	0	1
Taxotere	0	3
Topotecan	47	44
XELOX (capecitabine and oxaliplatin)	0	3
Total number of courses of chemotherapy	666	1124

* Clinical trial

Publications

Scholarly books, monographs and chapters

Ngu S.F. and Chan K.K.L., Abdominal Hysterectomy: Instrumentation and Apparatuses, In: Ibrahim Alkatout, Liselotte Mettler, Hysterectomy A Comprehensive Surgical Approach. Springer, Cham, 2018, 1049-1057. http://dx.doi.org/10.1007/978-3-319-22497-8_82.

Ngu S.F. and Chan K.K.L., Abdominal Hysterectomy: Preparation, In: Ibrahim Alkatout, Liselotte Mettler, Hysterectomy A Comprehensive Surgical Approach. Springer, Cham, 2018, 1041-1047. http://dx.doi.org/10.1007/978-3-319-22497-8_81.

Tse K.Y., Research in gynaecological cancers , In: Clinical Trial Center, the University of Hong Kong, 醫與研. Hong Kong, Health Action, 2018.

Journal publications

Chan K.K., Wong G.W., Wong E.S.Y., Chan K.K.L., Ip P.C.P., Tse K.Y. and Cheung A.N.Y., Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma, International Journal of Cancer. 2018. <http://dx.doi.org/10.1002/ijc.31535>.

Chan K.K.L., Siu K.Y., Jiang Y., Wang J., Leung T.H.Y. and Ngan H.Y.S., Estrogen receptor modulators genistein, daidzein and ERB-041 inhibit cell migration, invasion, proliferation and sphere formation via modulation of FAK and PI3K/AKT signaling in ovarian cancer, Cancer Cell Int. 2018, 18:65. <http://dx.doi.org/10.1186/s12935-018-0559-2>.

Chen K., Liu X., Mak S.L., Yung M.H., Leung T.H.Y., Xu D., Ngu S.F., Chan K.K.L., Yang H.J., Ngan H.Y.S. and Chan D.W., Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways, Theranostics. 2018, 8: 423-436. <http://dx.doi.org/10.7150/thno.22377>.

- Cheung V.Y.T. and Tse K.Y. Vulval Hemangioma. *J Obstet Gynaecol Can.* 2018 Jun;40(6):641. doi: 10.1016/j.jogc.2017.02.004. Epub 2017 May 4. No abstract available.
- Garland S.M., Pitisuttithum P., Ngan H.Y.S., Cho C.H., Lee C.Y., Chen C.A., Yang Y.C., Chu T.Y., Twu N.F., Samakoses R., Takeuchi Y., Cheung T.H., Kim S.C., Huang L.M., Kim B.G., Kim Y.T., Kim K.H., Song Y.S., Lalwani S., Kang J.H., Sakamoto M., Ryu H.S., Bhatla N., Yoshikawa H., Ellison M.C., Han S.R., Moeller E., Murata S., Ritter M., Sawata M., Shields C., Walia A., Perez G. and Luxembourg A., Efficacy, Immunogenicity, and Safety of a 9-Valent Human Papillomavirus Vaccine: Subgroup Analysis of Participants From Asian Countries, *J Infect Dis.* 2018, 218(1): 95-108. <http://dx.doi.org/10.1093/infdis/jiy133>.
- Kim J.W., Mahner S., Wu L.Y., Shoji T., Kim B.G., Zhu J.Q., Takano T., Park S.Y., Kong B.H., Wu Q., Wang K.L., Ngan H.Y., Liu J.H., Wei L.H., Mitrica I., Zhang P., Crescenzo R., Wang Q., Cox C.J., Harter P. and du Bois A. Pazopanib Maintenance Therapy in East Asian Women With Advanced Epithelial Ovarian Cancer: Results From AGO-OVAR16 and an East Asian Study. *Int J Gynecol Cancer.* 2018 Jan;28(1):2-10.
- Kwong A., HO Ho C.W.J., Shin V.Y., Kurian A.W., Tai E., Esserman L.J., Weizel J.N., Lin P.H., Field M., Domcheck S.M., Ngan H.Y.S., Ma E.S.K., Chan T.L. and Ford J.M., Rapid detection of BRCA1/2 recurrent mutations in Chinese breast and ovarian cancer patients with multiplex SNaPshot genotyping panels, *Oncotarget.* 2018, 9(8): 7832-7843. <http://dx.doi.org/10.18632/oncotarget.23471>.
- Lam W.L., Yeung W.F., Wong M.K., Cheung C.W., Chan K.K.L., Ngan H.Y.S., Wong C.K.H., Chen H. and Lao L., Combined electroacupuncture and auricular acupuncture for postoperative pain after abdominal surgery for gynecological diseases: study protocol for a randomized controlled trial, *Trials.* 2018, 19: 8. <http://dx.doi.org/10.1186/s13063-017-2359-8>.
- Leung L.L., Yung M.H., Ngan H.Y.S. and Chan D.W., Study of hedgehog signaling in cervical cancer, *ESMO Open. BMJ,* 2018, 3: A89-A89. <http://dx.doi.org/10.1136/esmoopen-2018-EACR25.214>.

- Leung T.H., Tang H.W., Siu M.K., Chan D.W., Chan K.K., Cheung A.N. and Ngan H.Y. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness. *J Pathol.* 2018 Feb;244(2):151-163. doi: 10.1002/path.4991. Epub 2017 Dec 19.
- Liu S., Chan K.K.L., Chu K.H., Wei N., Lau S.K., Ngu S.F., Chu M.Y.M., Tse K.Y., Ip P.C.P., Ng E.K.O., Cheung A.N.Y. and Ngan H.Y.S., Oncogenic microRNA signature for early diagnosis of cervical intraepithelial neoplasia and cancer, *Mol Oncol.* 2018, 12: 2009-2022. <http://dx.doi.org/10.1002/1878-0261.12383>.
- Meng Y., Chen C.W., Yung M.H., Sun W., Sun J., Li Z., Li J., Li Z., Zhou W., Liu S., Cheung A.N.Y., Ngan H.Y.S., Braisted J.C., Kai Y., Peng W., Tzatsos A., Li Y., Dai Z., Zheng W., Chan D.W. and Zhu W., DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer, *Cancer Letters.* 2018, 428: 104-116. <http://dx.doi.org/10.1016/j.canlet.2018.04.029>.
- Ngan H.Y.S., Seckl M.J., Berkowitz R.S., Xiang Y., Golfier F., Sekharan P.K., Lurain J.R. and Massuger L. Update on the diagnosis and management of gestational trophoblastic disease. *Int J Gynaecol Obstet.* 2018 Oct;143 Suppl 2:79-85. doi: 10.1002/ijgo.12615.
- Ng S.F., Chu M.Y.M., Tse K.Y., Chan K.K.L., Ip P.C.P., Cheung A.N.Y. and Ngan H.Y.S., Role Of Lymphadenectomy And Vincristine, Actinomycin-D, and Cyclophosphamide Chemotherapy in Malignant Ovarian Germ Cell Tumors, *European Journal of Gynaecological Oncology.* 2018, 39(1): 63-69. <http://dx.doi.org/10.12892/ejgo3763.2018>.
- Ng S.F., Chu M.M.Y., Ip P.P.C. and Ngan H.Y.S. Vulvar Hidradenitis Suppurativa: Is the Mass Malignant? *J Obstet Gynaecol Can.* 2018 Jan;40(1):1. doi: 10.1016/j.jogc.2016.10.015. Epub 2017 Mar 31.
- Ng S.F., Wei N., Kwan T.T.C., Chu M.M.Y., Tse K.Y., Chan K.K.L. and Ngan H.Y.S. Impact of different educational interventions on psychosocial well-being of women with a positive high-risk human papillomavirus and normal cervical cytology: a randomised trial. *J Psychosom Obstet Gynaecol.* 2018 Jun;39(2):146-155. doi: 10.1080/0167482X.2017.1312335. Epub 2017 Apr 10.

- Tang K.S., Yue P.Y.K., Ip P.C.P., Huang R.L., Lai H.C., Cheung A.N.Y., Tse K.Y., Ngan H.Y.S. and Wong A.S.T., Soluble E-cadherin promotes tumor angiogenesis and localizes to exosome surface, *Nature Communications*. 2018, 9: 2270. <http://dx.doi.org/10.1038/s41467-018-04695-7>.
- Tse K.Y., Chiu W.H.K., Chan K.K.L., Chu M.Y.M., Ngu S.F., Cheung A.N.Y., Ngan H.Y.S. and Ip P.C.P., A Case Series of Five Patients With Pure or Mixed Gestational Epithelioid Trophoblastic Tumors and a Literature Review on Mixed Tumors, *American Journal of Clinical Pathology*. 2018 Aug 30;150(4):318-332. <http://dx.doi.org/10.1093/ajcp/aqy039>.
- Wong G.W., Cheung L.Y., Ip P.C.P., Ngan H.Y.S. and Cheung A.N.Y., Amyloid Precursor Protein Overexpression in Down Syndrome Trophoblast Reduces Cell Invasiveness and Interferes with Syncytialization, *The American Journal of Pathology*. 2018, 188(10): 2307-17.
- Wong J.H., Sze S.C.W., Ng T.B., Cheung R.C.F., Tam C., Zhang K.Y., Dan X., Chan Y.S., Shing Cho W.C., Ng C.C.W., Waye M.M.Y., Liang W., Zhang J., Yang J., Ye X., Lin J., Ye X., Wang H., Liu F., Chan D.W., Ngan H.Y.S., Sha O., Li G., Tse R., Tse T.F. and Chan H. Apoptosis and Anti-cancer Drug Discovery: The Power of Medicinal Fungi and Plants. *Curr Med Chem*. 2018;25(40):5613-5630. Review.
- Xiang L., Jiang W., Ye S., He T., Pei X., Li J., Chan D.W., Ngan H.Y.S., Li F., Tao P., Shen X., Zhou X., Wu X., Yang G. and Yang H., ERBB2 mutation: A promising target in non-squamous cervical cancer, *Gynecologic Oncology*. 2018, 148(2): 311-316. <http://dx.doi.org/10.1016/j.ygyno.2017.12.023>.
- Ying L., Yan F., Meng Q., Yu L., Yuan X., Gantier M.P., Williams B.R., Chan D.W., Shi L., Tu Y., Ni P., Wang X., Chen W., Zang X., Xu D. and Hu Y., PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and FOXP3 immune markers, *OncoImmunology*. Taylor & Francis, 2018, 7, e1433520. <http://dx.doi.org/10.1080/2162402X.2018.1433520>
- Yung M.H., Tang W.M., Cai C.H., Leung T.H.Y., Ngu S.F., Chan K.K.L., Xu D., Yang H.U.I.J.U.A.N., Ngan H.Y.S. and Chan D.W., GRO- α and IL-8 enhance

ovarian cancer metastatic potential via the CXCR2-mediated TAK1/NFκB signaling cascade, *Theranostics*. 2018, 8: 1270-1285. <http://dx.doi.org/10.7150/thno.22536>.

Zhou W., Sun W., Yung M.H., Dai S., Cai Y., Chen C.W., Meng Y., Lee J.B., Braisted J.C., Xu Y., Southall N.T., Shinn P., Huang X., Song Z., Chen X., Kai Y., Cai X., Li Z., Hao Q., Cheung A.N.Y., Ngan H.Y.S., Liu S., Barak S., Hao J., Dai Z., Tzatsos A., Peng W., Pei H., Han Z., Chan D.W., Zheng W. and Zhu W., Autocrine activation of JAK2 by IL-11 promotes platinum drug resistance, *Oncogene*. 2018, 37(29): 3981-3997. <http://dx.doi.org/10.1038/s41388-018-0238-8>.

Abstracts

Chan D.W., Chen R. and Ngan H.Y.S., Targeting lipid metabolism with a metabolic inhibitor cocktail eradicates peritoneal metastases of ovarian cancer, Cold Spring Harbour Asia: Cancer & Metabolism. 26-30 March, 2018 Suzhou, China. 2018.

Chen R., Ngan H.Y.S. and Chan D.W., Targeting lipid metabolism eradicates peritoneal metastases of ovarian cancer, AACR Annual Meeting 2018, April 14-18, 2018 McCormick Place North/South Chicago, Illinois. 2018.

Ip P.C.P., Yu Y., Cheung C.L., Cheuk W., Cheung E., Wong W.C., Lee V., Chan W.K. and Tse K.Y., Female Genital melanomas: A clinicopathologic and PD-L1 expression study, The United States and Canadian Academy of Pathology 107th Annual Meeting. 2018.

Leung L.L., Yung M.H., Ngan H.Y.S. and Chan D.W., The secretary miR-141 facilitates ovarian cancer metastasis through reprogramming stromal fibroblast cells in pre-metastatic niches formation, the 25th Biennial Congress of the European Association for Cancer Research (EACR25). 2018. <http://dx.doi.org/10.1136/esmoopen-2018-EACR25.214>.

Liu S., Chan K.K.L., Chu K.H., Ngu S.F., Chu M.Y.M., Tse K.Y., Wei N., Lau S.K., Cheung A.N.Y. and Ngan H.Y.S., Comparison of Roche cobas test and HC2 test for the detection of high-risk HPV in a population-based study., 32nd International Papillomavirus Conference. 2018.

Ngu S.F., Chan K.K.L., Tse K.Y., Chu M.Y.M. and Ngan H.Y.S., Malignant Transformation of Ovarian Mature Cystic Teratoma, ASGO 5th International Workshop on Gynecologic Oncology, Suwon, South Korea. 2018.

Ngu S.F., Chan K.K.L., Tse K.Y., Chu M.Y.M., Ip P.C.P., Cheung A.N.Y. and Ngan H.Y.S., Positive Surgical Margin At Cervical Conization For High-grade Squamous Intraepithelial Lesion: Does It Matter?, 17th Biennial Meeting of the International Gynecologic Cancer Society, Kyoto, Japan . 2018.

Editorship, Invited Lectures and Keynote Speeches

Chan D.W., The tumor microenvironment on ovarian cancer progression and the potential target-based therapy, In: University Grants Committee, Hong Kong, RGC Public Lectures: Cancer Therapy: Immunotherapy and Medicine. 2018.

Chan K.K.L., Case Sharing- use of PARP-I for Ovarian Cancer, International Society of Precision Cancer Medicine (ISPCM) conference 2018 Busan, Korea 3/2018.

Chan K.K.L., Fertility Sparing Treatment in Gynaecological Malignancies, FOCUS in O&G 2018 Congress. 2018.

Chan K.K.L., Robotic Surgery In Gynaecological Cancer, Hong Kong College of Obstetrics and Gynaecology 30th anniversary symposium. 2018. (Publication No. : 292401; Weighting : 1.0000)Ngan H.Y.S., " Cervical Cancer and HPV Disease" and presented 2 topics on Tips and Tricks on "High risk HPV positive –cytology negative-what to do?" and "Abnormal glandular cell at Pap Smear", Meet the Expert Session, Malaysian International Scientific Congress of O&G 2018, Kuala Lumpur, Malaysia, July 26-29. 2018.

Ngan H.Y.S., "Prognostic and predicting factors including HPV" at the Multidisciplinary Tumour Broad on "Recurrent cervical cancer", European Society of Medical Oncology (ESMO) Asia Congress, Singapore, November 23-25, 2018.

Ngan H.Y.S., 17th Biennial Meeting of the International Gynecologic Cancer Society (IGCS), Kyoto, Japan, September 13-16, "Surgical management of GTD" at the Young Doctors' forum and to deliver a talk at the main conference on "How

can we improve FIGO staging”. 2018.

Ngan H.Y.S., Advances in Cervical Cancer Screening Beyond the Pap Smear, RCOG World Congress 2018, Singapore, March 21-24. 2018.

Ngan H.Y.S., Cervical Cancer Prevention and Control, 2018 New Advances in Management of Cervical Diseases Workshop, Wenzhou, China, April 21. 2018.

Ngan H.Y.S., Cervical Cancer Prevention and Control, The 2nd HN -SCCP cervical cancer precancerous lesion and cervical cancer hotspot conference, Xiangya Hospital, Central South University, Hunan, China, May 5-6. 2018.

Ngan H.Y.S., Choice of Treatment Modalities in Cervical Cancer, The 3rd Oriental Congress of Obstetrics and Gynecology, Shanghai, China, July 13-15. 2018.

Ngan H.Y.S., Current Advancements of PARP inhibitor in Europe/HK, Ovarian & Breast Cancer – Advancements in Diagnostic & Therapeutic Landscape Exchange Meeting, Hong Kong, 27 January. 2018.

Ngan H.Y.S., Endometrial Cancer – Current Management, Malaysian International Scientific Congress of O&G: Where Advanced Technology, Scientific Evidence & Clinical Skills Meet, Penang, Malaysia, March 25. 2018.

Ngan H.Y.S., Fertility Sparing Options in the Management of Gynaecological Cancers, The ASGO symposium, Malaysian International Scientific Congress of O&G 2018, Kuala Lumpur, Malaysia, July 26-29. 2018.

Ngan H.Y.S., How to decide which treatment is appropriate in cervical cancer, The 4th Chinese Society of Colposcopy and Cervical Pathology (CSCCP) conference, Shenzhen China, May 24-27. 2018.

Ngan H.Y.S., Maintenance Therapy in Ovarian Cancer, The First Ovarian Cancer Summit 2018, Beijing, China, June 30. 2018.

Ngan H.Y.S., Minimally invasive surgery for early stage Cervical Cancer, 20th Seminar of Standardized Treatment and Progress of Gynecologic Cancers, Symposium of Precision Medicine in Gynecological Oncology, Shanghai, China, November 9-11. 2018.

- Ngan H.Y.S., Screening and management of pre-invasive disease in AOGIN countries, The Asia Oceania Research Organization on Genital Infection and Neoplasia (AOGIN) conference and the 32th International Papillomavirus Conference (IPVC), Sydney, Australia, October 2-6. 2018.
- Ngan H.Y.S., The training of a gynaecological oncologist, Chongqing, China, March 30. 《第十五届妇科肿瘤学 术大会暨中国妇科肿 瘤青年医师高峰论坛》，2018.
- Ngan H.Y.S., Trophoblastic disease – current management, Pre-congress workshop, Malaysian International Scientific Congress of O&G 2018, Kuala Lumpur, Malaysia, July 26-29. 2018.
- Ngan H.Y.S., Updates on Management Options for Gestational Trophoblastic Disease, RCOG World Congress 2018, Singapore, March 21-24. 2018.
- Ngan H.Y.S., Updates on the management of Gestational Trophoblastic Diseases, Malaysian International Scientific Congress of O&G: Where Advanced Technology, Scientific Evidence & Clinical Skills Meet, Penang, Malaysia, March 25. 2018.
- Ngan H.Y.S., “Cancer cervix – When to use adjuvant treatment and managing advanced disease”, Pre-congress workshop, Malaysian International Scientific Congress of O&G 2018, Kuala Lumpur, Malaysia, July 26-29. 2018.
- Ngu S.F., Diagnosis & Management Of Abnormal Ps & Cin In Adolescent, Hospital Authority Obstetrics and Gynaecology Commissioned Training on 2017/18. 2018.
- Ngu S.F., HPV test vs PAP for Cervical Screening, Hong Kong Sanatorium & Hospital CME in Obstetrics & Gynaecology. 2018.
- Ngu S.F., HPV test vs PAP for Cervical Screening, Update on Management of Gynaecological Cancer, Postgraduate Study Day, Department of Obstetrics & Gynaecology, The University of Hong Kong. 2018.
- Ngu S.F., Self-sampling cervical cancer screening, 33rd The Royal Thai College of

Obstetricians and Gynaecologists Annual Meeting, Dusit Thani, Pattaya City, Thailand. 2018.

Tse K.Y., Multi-disciplinary team practice for ovarian cancer in Hong Kong, Macau Association of Precision Medicine. 2018.

Tse K.Y., Vulval intraepithelial neoplasia, The XXII FIGO World Congress of Gynecology and Obstetrics. 2018.

Prizes and Awards

Ngan H.Y.S., Chan K.K.L., Tse K.Y., Chu M.Y.M., Ngu S.F. and Hui S., QMH/TYH Outstanding Teams (Walk Together with One Heart), HKWC cum QMH/TYH Outstanding Staff & Teams Award and Young Achiever Award for 2018.

Ngan H.Y.S., Recognition of Women Obstetricians/Gynaecologists at the General Assembly, XXII World Congress of Gynecology and Obstetrics, 13-19 October, 2018 Rio de Janeiro, Brazil. 2018.

Ngu S.F., Travel Grant for Young Oncologists for ESMO Asia 2018, European Society for Medical Oncology (ESMO) / Hong Kong Cancer Therapy Society. 2018.

